Revvity Sees Steady Growth On Rising Demand From Pharma/Biotech Customers

Revvity Inc. (NYSE:RVTY) on Monday reported fourth quarter 2025 adjusted earnings of $1.70 per share, up 19.7% year over year, beating the consensus of $1.55.Adjusted operating income was $229 million, as compared to $221 million a year ago.Adjusted operating profit margin was 29.7% compared to 30.3% a year ago.The life sciences and diagnostics company reported sales of $772.06 million, up 6% (+4% organic growth), surpassing the consensus of $761.29 million.“We finished 2025 on a strong note by delivering r ...